Skip to main content

Advertisement

SpringerLink
Log in

Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient

  • Hypertension (DS Geller and DL Cohen, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The prevalence of hypertension and erectile dysfunction has steadily increased, and greater than 40% of men with erectile dysfunction concurrently share a diagnosis of hypertension. The treatment of the patient with both diseases poses a clinical challenge as both are closely correlated and share multiple overlapping risk factors.To address the recognized knowledge gap among clinicians who care for these patients, we will review the current literature on the diagnosis and treatment of erectile dysfunction in the hypertensive patient and will provide recommendations for the management of this challenging patient population.

Recent Findings

The pharmacological treatment of hypertension may adversely affect sexual function, and certain treatments for erectile dysfunction are contraindicated or cautioned against with certain antihypertensive agents.

Summary

In review of the literature, we find that the clinician should opt to use an angiotensin-receptor blocker followed by an angiotensin-converting enzyme inhibitor or calcium channel blocker for the treatment of hypertension in patients with erectile dysfunction. Other agents require careful consideration for adverse effects on sexual function. Men with erectile dysfunction should be assessed for cardiovascular fitness for sexual activity, and PDE-5 inhibitors remain the first-line treatment for erectile dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013(133):1–8.

  2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043–50.

    Article  CAS  PubMed  Google Scholar 

  3. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140(11):945–50.

    Article  PubMed  Google Scholar 

  4. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–55.

    Article  CAS  PubMed  Google Scholar 

  5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brownson RC, Boehmer TK, Luke DA. Declining rates of physical activity in the United States: what are the contributors? Annu Rev Public Health. 2005;26:421–43.

    Article  PubMed  Google Scholar 

  7. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46(2):280–6.

    Article  CAS  PubMed  Google Scholar 

  8. Natali A, Vichi S, Landi P, et al. Coronary artery disease and arterial hypertension: clinical, angiographic and follow-up data. J Intern Med. 2000;247(2):219–30.

    Article  CAS  PubMed  Google Scholar 

  9. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19(7):1550–8.

    Article  CAS  PubMed  Google Scholar 

  10. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  CAS  PubMed  Google Scholar 

  11. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

    Article  CAS  PubMed  Google Scholar 

  12. Mensah GA, Croft JB, Giles WH. The heart, kidney, and brain as target organs in hypertension. Cardiol Clin. 2002;20(2):225–47.

    Article  PubMed  Google Scholar 

  13. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S30–7.

    Article  PubMed  Google Scholar 

  14. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens. 2006;24(10):1907–14.

    Article  CAS  PubMed  Google Scholar 

  15. Bardage C, Isacson DG. Hypertension and health-related quality of life. An epidemiological study in Sweden. J Clin Epidemiol. 2001;54(2):172–81.

    Article  CAS  PubMed  Google Scholar 

  16. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003;21(7):1283–9.

    Article  CAS  PubMed  Google Scholar 

  17. Pickering TG. Mental stress as a causal factor in the development of hypertension and cardiovascular disease. Curr Hypertens Rep. 2001;3(3):249–54.

    Article  CAS  PubMed  Google Scholar 

  18. Kawachi I, Colditz GA, Ascherio A, et al. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA. J Epidemiol Community Health. 1996;50(3):245–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kaplan GA, Salonen JT, Cohen RD, Brand RJ, Syme SL, Puska P. Social connections and mortality from all causes and from cardiovascular disease: prospective evidence from eastern Finland. Am J Epidemiol. 1988;128(2):370–80.

    Article  CAS  PubMed  Google Scholar 

  20. Cragg JJ, Noonan VK, Noreau L, Borisoff JF, Kramer JK. Neuropathic pain, depression, and cardiovascular disease: a national multicenter study. Neuroepidemiology. 2015;44(3):130–7.

    Article  PubMed  Google Scholar 

  21. Werner MU. The relationship between chronic pain and cardiovascular disease: squaring the circle? Scand J Pain. 2016;13:134–5.

    Article  PubMed  Google Scholar 

  22. Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157(6):638–48.

    Article  PubMed  Google Scholar 

  23. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens. 1998;16(10):1407–14.

    Article  CAS  PubMed  Google Scholar 

  24. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314(26):1657–64.

    Article  CAS  PubMed  Google Scholar 

  25. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press. 1997;6(6):357–64.

    Article  CAS  PubMed  Google Scholar 

  26. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357–62.

    Article  PubMed  Google Scholar 

  27. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000;164(4):1188–91.

    Article  CAS  PubMed  Google Scholar 

  28. • Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996–3002. This notable paper provides substantial evidence that erectile dysfunction serves as a harbinger of cardiovascular disease in men.

    Article  CAS  PubMed  Google Scholar 

  29. Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M–23M.

    Article  PubMed  Google Scholar 

  30. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–88.

    Article  PubMed  Google Scholar 

  31. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4(1):57–65.

    Article  PubMed  Google Scholar 

  32. Gatti A, Mandosi E, Fallarino M, et al. Metabolic syndrome and erectile dysfunction among obese non-diabetic subjects. J Endocrinol Investig. 2009;32(6):542–5.

    Article  CAS  Google Scholar 

  33. Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  34. Hirshkowitz M, Karacan I, Arcasoy MO, Acik G, Narter EM, Williams RL. Prevalence of sleep apnea in men with erectile dysfunction. Urology. 1990;36(3):232–4.

    Article  CAS  PubMed  Google Scholar 

  35. Holden CA, McLachlan RI, Pitts M, et al. Determinants of male reproductive health disorders: the men in Australia Telephone Survey (MATeS). BMC Public Health. 2010;10:96.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ashton WD, Nanchahal K, Wood DA. Body mass index and metabolic risk factors for coronary heart disease in women. Eur Heart J. 2001;22(1):46–55.

    Article  CAS  PubMed  Google Scholar 

  37. Health USDo, Services H. Physical activity and health: a report of the Surgeon General. diane Publishing; 1996.

  38. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA. 2000;283(14):1829–36.

    Article  CAS  PubMed  Google Scholar 

  39. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50–6.

    Article  CAS  PubMed  Google Scholar 

  40. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151–7.

    Article  PubMed  Google Scholar 

  41. Jonler M, Moon T, Brannan W, Stone NN, Heisey D, Bruskewitz RC. The effect of age, ethnicity and geographical location on impotence and quality of life. Br J Urol. 1995;75(5):651–5.

    Article  CAS  PubMed  Google Scholar 

  42. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res. 2000;12(Suppl 4):S144–6.

    Article  PubMed  Google Scholar 

  43. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13(3):159–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25(2):284–91.

    Article  PubMed  Google Scholar 

  45. Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med. 2013;10(2):551–61.

    Article  CAS  PubMed  Google Scholar 

  46. Scranton RE, Lawler E, Botteman M, et al. Effect of treating erectile dysfunction on management of systolic hypertension. Am J Cardiol. 2007;100(3):459–63.

    Article  PubMed  Google Scholar 

  47. • Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14. This paper provides a good diagnosis algorithm and additional studies for men who present for the evaluation of erectile dysfunction.

    Article  PubMed  Google Scholar 

  48. • Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–65. This review paper provides detailed background on the pathophysiology of erectile dysfunction and major treatments.

    Article  CAS  PubMed  Google Scholar 

  49. Persu C, Cauni V, Gutue S, Albu ES, Jinga V, Geavlete P. Diagnosis and treatment of erectile dysfunction—a practical update. J Med Life. 2009;2(4):394–400.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.

    Article  CAS  PubMed  Google Scholar 

  51. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol. 1997;158(4):1388–90.

    Article  CAS  PubMed  Google Scholar 

  52. Polonsky TS, Taillon LA, Sheth H, Min JK, Archer SL, Ward RP. The association between erectile dysfunction and peripheral arterial disease as determined by screening ankle-brachial index testing. Atherosclerosis. 2009;207(2):440–4.

    Article  CAS  PubMed  Google Scholar 

  53. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002;359(9304):417–25.

    Article  PubMed  Google Scholar 

  54. Diaz-Arjonilla M, Schwarcz M, Swerdloff RS, Wang C. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res. 2009;21(2):89–98.

    Article  CAS  PubMed  Google Scholar 

  55. Sanders SA, Milhausen RR, Crosby RA, Graham CA, Yarber WL. Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage? J Sex Med. 2009;6(5):1451–6.

    Article  CAS  PubMed  Google Scholar 

  56. Lu H, Tang Z, Shen Z, et al. Sildenafil use and relevant risk factors among middle-aged or elderly male clients of female commercial sex workers in the central areas of Guangxi, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35(11):1218–22.

    PubMed  Google Scholar 

  57. Kim AA, Kent CK, Klausner JD. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000-2001. AIDS. 2002;16(10):1425–8.

    Article  PubMed  Google Scholar 

  58. Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med. 2005;118(6):571–7.

    Article  CAS  PubMed  Google Scholar 

  59. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108–13.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85.

    Article  PubMed  Google Scholar 

  61. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des. 2008;14(35):3700–14.

    Article  CAS  PubMed  Google Scholar 

  62. Seidman SN, Roose SP. The relationship between depression and erectile dysfunction. Curr Psychiatry Rep. 2000;2(3):201–5.

    Article  CAS  PubMed  Google Scholar 

  63. Shiri R, Koskimaki J, Tammela TL, Hakkinen J, Auvinen A, Hakama M. Bidirectional relationship between depression and erectile dysfunction. J Urol. 2007;177(2):669–73.

    Article  PubMed  Google Scholar 

  64. •• Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clin Proc. 2012;87(8):766–78. This article provides detailed specific guidelines for cardiovascular risk stratification of men who wish to engage in sexual activity.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Jackson G. Sexual response in cardiovascular disease. J Sex Res. 2009;46(2–3):233–6.

    Article  PubMed  Google Scholar 

  66. Jackson G. Treatment of erectile dysfunction in patients with cardiovascular disease: guide to drug selection. Drugs. 2004;64(14):1533–45.

    Article  CAS  PubMed  Google Scholar 

  67. Jackson G. Sexual intercourse and stable angina pectoris. Am J Cardiol. 2000;86(2A):35F–7F.

    Article  CAS  PubMed  Google Scholar 

  68. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56(2):302–6.

    Article  CAS  PubMed  Google Scholar 

  69. Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med. 2009;6(Suppl 3):254–61.

    Article  PubMed  Google Scholar 

  70. Hannan JL, Heaton JP, Adams MA. Recovery of erectile function in aging hypertensive and normotensive rats using exercise and caloric restriction. J Sex Med. 2007;4(4 Pt 1):886–97.

    Article  PubMed  Google Scholar 

  71. Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol. 1994;140(11):1003–8.

    Article  CAS  PubMed  Google Scholar 

  72. Guay AT, Perez JB, Heatley GJ. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract. 1998;4(1):23–6.

    Article  CAS  PubMed  Google Scholar 

  73. Horasanli K, Boylu U, Kendirci M, Miroglu C. Do lifestyle changes work for improving erectile dysfunction? Asian J Androl. 2008;10(1):28–35.

    Article  CAS  PubMed  Google Scholar 

  74. Guay AT, Face MD, André T, Perez M, Jesus B, Heatley M, et al. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract. 1998;4(1):23–6.

    Article  CAS  PubMed  Google Scholar 

  75. Riley A. The role of the partner in erectile dysfunction and its treatment. Int J Impot Res. 2002;14(Suppl 1):S105–9.

    Article  PubMed  Google Scholar 

  76. Ende J. Organic impotence. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston; 1990.

  77. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753–69.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Viigimaa M, Vlachopoulos C, Lazaridis A, Doumas M. Management of erectile dysfunction in hypertension: tips and tricks. World J Cardiol. 2014;6(9):908–15.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359–64.

    Article  CAS  Google Scholar 

  80. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002;58(3):177–80.

    Article  CAS  PubMed  Google Scholar 

  81. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–7.

    Article  CAS  PubMed  Google Scholar 

  82. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  83. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928–32.

    Article  CAS  PubMed  Google Scholar 

  84. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004;1:2–16.

    Article  PubMed  CAS  Google Scholar 

  85. Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl. 2006;8(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  86. Williams GH, Croog SH, Levine S, Testa MA, Sudilovsky A. Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide. J Hypertens Suppl. 1987;5(1):S29–35.

    CAS  PubMed  Google Scholar 

  87. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 Pt 1):8–14.

    Article  CAS  PubMed  Google Scholar 

  88. Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–40.

    Article  Google Scholar 

  89. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–8.

    Article  PubMed  Google Scholar 

  90. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  CAS  PubMed  Google Scholar 

  91. Loffing J, Kaissling B. Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human. Am J Physiol Ren Physiol. 2003;284(4):F628–43.

    Article  CAS  Google Scholar 

  92. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644–8.

    Article  CAS  Google Scholar 

  93. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol. 1997;157(5):1920–5.

    Article  CAS  PubMed  Google Scholar 

  94. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29–34.

    Article  CAS  PubMed  Google Scholar 

  95. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321(5):336–41.

    Article  CAS  PubMed  Google Scholar 

  96. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11(10):1244–7.

    Article  CAS  PubMed  Google Scholar 

  97. Baumhakel M, Schlimmer N, Bohm M, Investigators D-I. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20(5):493–500.

    Article  CAS  PubMed  Google Scholar 

  98. Suzuki H, Tominaga T, Kumagai H, Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens. 1988;6(4):S649–51.

    Article  CAS  Google Scholar 

  99. Omvik P, Thaulow E, Herland OB, Eide I, Midha R, Turner RR. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens. 1993;11(1):103–13.

    Article  CAS  PubMed  Google Scholar 

  100. Kroner BA, Mulligan T, Briggs GC. Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study. Ann Pharmacother. 1993;27(11):1329–32.

    Article  CAS  PubMed  Google Scholar 

  101. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.

    Article  PubMed  Google Scholar 

  102. Segraves RT, Madsen R, Carter CS, Davis JM. Erectile dysfunction associated with pharmacological agents. In: Segraves RT, Schoenberg HW, editors. Diagnosis and treatment of erectile disturbances: a guide for clinicians. Boston: Springer US; 1985. p. 23–63.

    Chapter  Google Scholar 

  103. Hogan MJ, Wallin JD, Baer RM. Antihypertensive therapy and male sexual dysfunction. Psychosomatics. 1980;21(3):234–7.

    Article  CAS  PubMed  Google Scholar 

  104. Keidan H. Letter: impotence during antihypertensive treatment. Can Med Assoc J. 1976;114(10):874.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Ahmad S. Hydralazine and male impotence. CHEST J. 1980;78(2):358.

    Article  CAS  Google Scholar 

  106. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–404.

    Article  CAS  PubMed  Google Scholar 

  107. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47–52.

    CAS  PubMed  Google Scholar 

  108. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Pt 1):1332–6.

    Article  CAS  PubMed  Google Scholar 

  109. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45(3):339–44. discussion 344-335

    Article  CAS  PubMed  Google Scholar 

  110. Shabsigh R, Duval S, Shah M, Regan TS, Juhasz M, Veltry LG. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin. 2007;23(10):2453–60.

    Article  CAS  PubMed  Google Scholar 

  111. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13(4):192–9.

    Article  CAS  PubMed  Google Scholar 

  112. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens. 2000;18(12):1865–9.

    Article  CAS  PubMed  Google Scholar 

  113. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2(6):856–64.

    Article  PubMed  CAS  Google Scholar 

  114. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens. 2001;14(1):70–3.

    Article  CAS  PubMed  Google Scholar 

  115. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004;17(12 Pt 1):1135–42.

    Article  CAS  PubMed  Google Scholar 

  116. Ishikura F, Beppu S, Hamada T, Khandheria BK, Seward JB, Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000;102(20):2516–21.

    Article  CAS  PubMed  Google Scholar 

  117. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 α-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172(5):1935–40.

    Article  PubMed  Google Scholar 

  118. Montague DK, Jarow JP, Broderick GA, et al. The management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230–9.

    Article  PubMed  Google Scholar 

  119. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med. 2006;3(5):901–9.

    Article  CAS  PubMed  Google Scholar 

  120. Martin AL, Huelin R, Wilson D, Foster TS, Mould JF. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction. J Sex Med. 2013;10(5):1389–400.

    Article  PubMed  Google Scholar 

  121. Pahlajani G, Raina R, Jones S, Ali M, Zippe C. Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med. 2012;9(4):1182–9.

    Article  PubMed  Google Scholar 

  122. Bettocchi C, Palumbo F, Spilotros M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med. 2010;7(1 Pt 1):304–9.

    Article  PubMed  Google Scholar 

  123. Falcone M, Rolle L, Ceruti C, et al. Prospective analysis of the surgical outcomes and patients’ satisfaction rate after the AMS spectra penile prosthesis implantation. Urology. 2013;82(2):373–6.

    Article  PubMed  Google Scholar 

  124. Stadelmann WK, Digenis AG, Tobin GR. Impediments to wound healing. Am J Surg. 1998;176(2A Suppl):39S–47S.

    Article  CAS  PubMed  Google Scholar 

  125. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6 Pt 1):2341–5.

    Article  PubMed  Google Scholar 

  126. Olives C, Myerson R, Mokdad AH, Murray CJ, Lim SS. Prevalence, awareness, treatment, and control of hypertension in United States counties, 2001-2009. PLoS One. 2013;8(4):e60308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale School of Medicine, PO Box 208058, New Haven, CT, 06520-8058, USA

    Jay Pravin Patel & Eric Hweegeun Lee

  2. Yale School of Management, New Haven, CT, USA

    Jay Pravin Patel & Eric Hweegeun Lee

  3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

    Carlos Ignacio Mena-Hurtado

  4. Fairfield, CT, USA

    Charles N. Walker

Authors
  1. Jay Pravin Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Hweegeun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos Ignacio Mena-Hurtado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles N. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles N. Walker.

Ethics declarations

Conflict of Interest

Jay Pravin Patel, Eric Hweegeun Lee, and Charles N. Walker declare that they have no conflict of interest.

Carlos Ignacio Mena reports personal fees from Medtronic, Cook, and Bard.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, J.P., Lee, E.H., Mena-Hurtado, C.I. et al. Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. Curr Cardiol Rep 19, 89 (2017). https://doi.org/10.1007/s11886-017-0889-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0889-z

Keywords

Search

Navigation